<DOC>
	<DOCNO>NCT02959944</DOCNO>
	<brief_summary>To evaluate safety efficacy ibrutinib combination prednisone subject newly diagnose moderate severe cGVHD .</brief_summary>
	<brief_title>Ibrutinib Combination With Corticosteroids Versus Placebo Combination With Corticosteroids Subjects With New Onset Chronic Graft Versus Host Disease ( cGVHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>New onset moderate severe cGVHD define 2014 NIH Consensus Development Project Criteria Need systemic treatment corticosteroid cGVHD No previous systemic treatment cGVHD ( include extracorporeal photopheresis [ ECP ] ) May receive immunosuppressant prophylaxis treatment acute GVHD dose medication must stable least 2 week prior Screening Age ≥12 year old Karnofsky Lansky ( subject &lt; 16 year ) performance status ≥60 Received previous systemic treatment cGVHD Inability begin prednisone dose ≥0.5 mg/kg/d treatment cGVHD Any uncontrolled infection active infection require ongoing systemic treatment Progressive underlie malignant disease posttransplant lymphoproliferative disease Known bleeding disorder Active hepatitis C virus ( HCV ) hepatitis B virus ( HBV )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic graft versus host disease</keyword>
	<keyword>PCYC1140</keyword>
	<keyword>PCYC1140IM</keyword>
	<keyword>1140</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>GVHD</keyword>
	<keyword>Steroid dependent</keyword>
	<keyword>refractory</keyword>
	<keyword>chronic</keyword>
	<keyword>PCI32765</keyword>
	<keyword>IMBRUVICA</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>immunology</keyword>
	<keyword>new onset graft versus host disease</keyword>
	<keyword>INTEGRATE</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>prednisone</keyword>
</DOC>